Answers are grounded in this paper and cite their sources.
Retrospective study evaluates FES-PET positivity related to genomic alterations in ER+ breast cancer, suggesting implications for therapy.
e15072 Background: 18 F-fluoroestradiol positron emission tomography (FES-PET) is a highly specific imaging modality for detecting estrogen receptor-positive (ER+) breast cancer (BC), particularly when biopsy is not feasible or conventional staging is equivocal. Endocrine therapy (ET) resistance often develops during ER+ BC treatment and arises from genomic alterations that promote estrogen-independent signaling and, for some alterations, reduced ER expression. As clinical use of FES-PET expands, understanding the potential impact of these alterations on FES-PET avidity is important. Therefore, we assessed the relationship between tumor genomic profiles and FES-PET positivity in ER+ BC. Methods: We conducted a single-center retrospective study of patients with histologically confirmed ER+ BC at diagnosis who underwent FES-PET/CT or PET/MR between 12/2023-8/2025 and had blood- or tissue-based genomic testing within 6 months of imaging. Human epidermal growth factor receptor 2-positive (HER2+) and negative (HER2-) tumors were included. FES-PET positivity was defined as SUVmax >1.5 in the most avid lesion, assessed by a board-certified nuclear radiologist. Results: Forty-three patients were included (4 local recurrences, 39 metastatic). FES-PET was positive in 22 patients, was non-avid in 9, had mixed ER+ and ER- disease in 2, was indeterminate in 2, and showed no evidence of disease in 8. Of the 9 non-avid FES-PET cases, 3 had ER+ disease on biopsy at metastatic recurrence, 4 had ER- disease, and 2 had mixed ER+ and ER- disease. Genomic profiling was performed via liquid biopsy (n = 33), tissue-based testing (n = 9), or both (n = 1). PIK3CA and TP53 mutations were the most frequent alterations seen in 15 and 11 patients, respectively; 9 patients with PIK3CA mutations and 6 with TP53 alterations had a positive FES-PET. ESR1 mutations were identified in 5 patients, 4 with a positive FES-PET. FGFR1 amplification was seen in 3 patients; one had a strongly positive FES-PET, one had mixed ER+ and ER- lesions, and one had a negative FES-PET despite ER+ disease. KRAS mutations were present in 3 patients; two had a positive FES-PET. The other had ER- disease at recurrence and negative FES-PET. RB1 loss was seen in 2 patients; one had a negative FES-PET in the setting of ER- disease at recurrence, the other had mixed ER+ and ER- lesions. ERBB2 mutations were identified in 2 patients; one had a positive FES-PET, the other had lesions too small to characterize. Conclusions: FES-PET is a valuable imaging tool, though false-negative results can occur and may limit its suitability for initial staging in advanced ER+ BC. In this cohort of ER+ BC patients undergoing FES-PET with concurrent genomic profiling, heterogeneity in FES avidity was seen across multiple genomic alterations associated with resistance to antiestrogen therapies. Further evaluation in a larger cohort is ongoing; updated findings will be presented at the meeting.
No takes yet. Share an insight, caveat, or question.
Michaels et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: